Business Context and Reporting Period
Elanco Animal Health Incorporated filed a Form 8-K regarding the completion of its acquisition of Bayer Aktiengesellschaft’s animal health business. The report date was July 30, 2020, with the acquisition and related financing closing on August 1, 2020; the filing was signed August 3, 2020. This is a transaction-focused filing and does not present a quarterly or annual operating period.
Key Financial and Transaction Metrics
- Acquisition consideration: Approximately $5.2 billion in cash, subject to customary post-closing adjustments, plus 72,946,429 shares of Elanco common stock.
- Term loan facility: $4.275 billion principal amount, with a seven-year maturity.
- Revolving credit facility: Up to $750 million, with a five-year maturity, including letter-of-credit and swingline sub-facilities.
- Financing use: Term loan proceeds and a portion of the revolver funded the acquisition, repayment of Elanco’s existing revolving facility, and related fees and expenses. Future revolver borrowings may fund working capital and general corporate purposes.
- Interest rates: Term loans bear interest at either base rate plus 0.75% or LIBOR plus 1.75%, with a 0.00% LIBOR floor. Initial revolver pricing is the same, subject to later ratings-based pricing.
- Debt amortization: Scheduled quarterly term-loan amortization equals 1.00% annually of the original principal amount, with the remaining balance due at maturity.
- Liquidity fees: The unused revolver commitment fee is initially 0.50% annually, subject to step-downs based on leverage.
- Collateral and guarantees: The senior facilities are secured by first-priority liens on substantially all borrower and guarantor assets and are guaranteed by specified wholly owned material subsidiaries.
- Financial covenants: Beginning with the quarter ending September 30, 2020, the revolver requires a maximum net total leverage ratio of 7.71 to 1.00 and a minimum interest coverage ratio of 2.00 to 1.00.
Material Changes Versus the Prior Comparable Period
- Elanco completed the acquisition of Bayer’s animal health business, materially expanding its operations and adding approximately $5.2 billion of cash acquisition consideration and new equity issuance.
- Elanco entered into new senior secured financing totaling up to $5.025 billion of initial term and revolving commitments.
- Elanco terminated its existing revolving credit facility on July 31, 2020. It had no principal or interest outstanding at termination, and all amounts due were paid.
- Elanco issued the consideration shares to a Bayer affiliate in a private placement exempt from Securities Act registration under Section 4(a)(2).
- Amendment No. 4 to the acquisition agreement addressed the deferred transfer of certain assets and employees and excluded India from specified restrictions on competing business activities.
Guidance, Outlook, Risks, and Unusual Items
- The filing does not provide operating guidance, revenue forecasts, profit forecasts, cash-flow forecasts, or margin targets.
- The acquisition creates substantial additional secured debt and related interest obligations. The credit agreement includes excess-cash-flow and certain asset-sale and debt-incurrence prepayment requirements.
- Debt covenants, restrictions on additional debt, liens, investments, dividends, acquisitions, asset sales, and other corporate actions may limit financial and operating flexibility.
- A default could permit lenders to accelerate amounts due and exercise remedies against collateral. A change of control is among the specified events of default.
- A 1.00% prepayment premium applies to certain term-loan repricing events during the first six months after closing.
- The filing states that required historical and pro forma financial information for the acquired business would be filed later by amendment. The provided text does not include those financial statements.
Investor Verification Items
- Verify the final cash purchase price and post-closing adjustments for the Bayer transaction.
- Review the subsequently filed historical and pro forma financial information for the acquired business.
- Confirm the amount drawn under the revolver at closing and Elanco’s consolidated debt and net leverage after the acquisition.
- Assess compliance with the 7.71-to-1.00 leverage covenant and 2.00-to-1.00 interest coverage covenant beginning September 30, 2020.
- Review the full credit agreement for mandatory prepayment provisions, collateral scope, covenant exceptions, and events of default.
- Evaluate the dilution from the 72,946,429 shares issued to Bayer and the acquisition’s effect on future revenue, earnings, cash flow, and margins.